Kopp Investment Advisors LLC lifted its holdings in shares of AtriCure Inc. (NASDAQ:ATRC) by 11.2% during the fourth quarter, HoldingsChannel.com reports. The firm owned 127,435 shares of the medical device company’s stock after acquiring an additional 12,836 shares during the quarter. AtriCure makes up 2.3% of Kopp Investment Advisors LLC’s investment portfolio, making the stock its 16th biggest holding. Kopp Investment Advisors LLC’s holdings in AtriCure were worth $2,324,000 as of its most recent SEC filing.
Other large investors have also modified their holdings of the company. Campbell & CO Investment Adviser LLC acquired a new position in shares of AtriCure during the third quarter worth $205,000. Teacher Retirement System of Texas acquired a new position in shares of AtriCure during the fourth quarter worth $203,000. HBK Investments L P acquired a new position in shares of AtriCure during the fourth quarter worth $255,000. Capital Fund Management S.A. lifted its holdings in shares of AtriCure by 57.3% during the fourth quarter. Capital Fund Management S.A. now owns 15,100 shares of the medical device company’s stock worth $275,000 after purchasing an additional 5,500 shares during the period. Finally, OxFORD Asset Management LLP acquired a new position in AtriCure in the third quarter valued at $457,000. Institutional investors own 87.50% of the company’s stock.
In other news, SVP Justin J. Noznesky sold 4,000 shares of the company’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $17.03, for a total transaction of $68,120.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 11.90% of the stock is currently owned by corporate insiders.
AtriCure Inc. (NASDAQ ATRC) opened at $19.65 on Monday. AtriCure Inc. has a fifty-two week low of $14.88 and a fifty-two week high of $25.18. The company has a current ratio of 2.58, a quick ratio of 1.87 and a debt-to-equity ratio of 0.23.
AtriCure (NASDAQ:ATRC) last announced its quarterly earnings data on Monday, February 26th. The medical device company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.13. AtriCure had a negative net margin of 15.39% and a negative return on equity of 16.74%. The firm had revenue of $46.06 million for the quarter, compared to analyst estimates of $45.85 million. During the same quarter in the prior year, the business earned ($0.27) earnings per share. The business’s quarterly revenue was up 11.8% compared to the same quarter last year. sell-side analysts forecast that AtriCure Inc. will post -0.83 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: This report was originally published by Ticker Report and is the property of of Ticker Report. If you are accessing this report on another website, it was copied illegally and republished in violation of U.S. and international copyright and trademark law. The original version of this report can be accessed at https://www.tickerreport.com/banking-finance/3257766/kopp-investment-advisors-llc-acquires-12836-shares-of-atricure-inc-atrc.html.
AtriCure Company Profile
AtriCure, Inc is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures.
Want to see what other hedge funds are holding ATRC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AtriCure Inc. (NASDAQ:ATRC).
Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.